Schizophrenia drug development may be 'de-risked' with new research tool

November 22, 2017

Researchers at Columbia University Medical Center (CUMC) and the New York State Psychiatric Institute (NYSPI) have identified biomarkers that can aid in the development of better treatments for schizophrenia.

The findings were published online today in JAMA Psychiatry.

In the past two decades, the pharmaceutical industry has spent over $2.5 billion to develop new schizophrenia drugs. But while many appear to be effective in animal models, most fail when tested in late-stage human clinical trials.

"While a great deal of money has been invested in developing schizophrenia drugs, a similar investment hasn't been made to develop biomarkers that could improve the reliability and consistency of test results," said Daniel Javitt, MD, PhD, professor of psychiatry and Director of the Division of Experimental Therapeutics at CUMC, Director of schizophrenia research at the Nathan Kline Institute for Psychiatric Research, and Co-Principal Investigator of the study.

The National Institute of Mental Health's FAST Initiative, which was established to validate the use of biomarkers to facilitate development, aligns with the 21st Century Cures Act passed last year by Congress. The legislation authorized the U.S. Food and Drug Administration to approve treatments based on biomarker data alone, and created a formal Biomarker Qualification Program.

In this context, FAST-Psychosis researchers identified biomarkers using MRI applications to support the development of drugs that target the glutamate system. Previous studies have shown that drugs such as phencyclidine (PCP or "angel dust") and ketamine, which block glutamate receptors, cause schizophrenia-like symptoms in healthy volunteers.

The researchers evaluated three potential biomarkers for detecting the effects of ketamine on human brain function. The largest effects were observed with a measuring increases in blood flow in the frontal regions of the brain. This response was detected consistently among individuals who were briefly exposed to ketamine, and reliably distinguished them from those who had been given a placebo. Another measure of the concentration of glutamate/glutamine was also sensitive to ketamine brain effects.

Overall, the biomarkers were successful in identifying over 90 percent of individuals who had received ketamine, and differentiating them from all of those in the placebo group.

"These results enable us to determine whether potential treatments will be effective against patients' symptoms by testing them first in and defining the best doses based on objective physiological data before conducting costly clinical trials," said Jeffrey Lieberman, MD, the Lawrence C. Kolb Professor and Chairman of the Department of Psychiatry at CUMC, and Principal Investigator of this study.

If the biomarkers are approved by the FDA, the developments of this study will be the first objective biomarkers registered to permit approval of new glutamate-modulating treatments for schizophrenia.

Explore further: Treating depression—an expert discusses risks, benefits of ketamine

Related Stories

Treating depression—an expert discusses risks, benefits of ketamine

October 20, 2017
Up to a third of patients with depression don't respond to traditional forms of treatment. For those patients, the dark fog that hovers over their lives feels like it will never lift. But a new treatment called ketamine has ...

Inflammatory biomarkers may impact risk of schizophrenia

November 3, 2017
(HealthDay)—Specific inflammatory biomarkers may impact the risk of developing schizophrenia, with a protective effect noted for C-reactive protein (CRP) and a risk-increasing effect for soluble interleukin-6 receptor (sIL-6R), ...

Researchers review progress of treating glutamate signalling in depression

March 17, 2017
Major depressive disorder (MDD) impacts 15 million Americans and is the leading cause of disability, yet current treatments possess limited efficacy. Ketamine, which has been repurposed as a rapidly acting antidepressant, ...

High levels of glutamate in brain may kick-start schizophrenia

April 18, 2013
An excess of the brain neurotransmitter glutamate may cause a transition to psychosis in people who are at risk for schizophrenia, reports a study from investigators at Columbia University Medical Center (CUMC) published ...

Disproving hypothesis clears path for research for new treatment options for schizophrenia

March 10, 2016
Researchers reported results from the first repeated-dose study of a dopamine-1 receptor (D1R) agonist for treating the cognitive and negative symptoms of schizophrenia today in the Journal of Psychopharmacology.

Heart study finds faulty link between biomarkers and clinical outcomes

July 14, 2017
Surrogate endpoints (biomarkers), which are routinely used in clinical research to test new drugs, should not be trusted as the ultimate measure to approve new health interventions in cardiovascular medicine, according to ...

Recommended for you

Thinking about germs makes people concerned about how they look

December 18, 2017
Simply thinking about potential infection seems to increase people's concerns about their own physical appearance, especially if they are chronic germ worriers, according to new research in Psychological Science. The findings ...

How much people earn is associated with how they experience happiness

December 18, 2017
People who earn more money tend to experience more positive emotions focused on themselves, while people who earn less take greater pleasure in their relationships and ability to connect with others, according to research ...

Could cognitive interventions be useful in treating depression?

December 18, 2017
A new study by experimental psychologists from the University of Bristol has examined whether cognitive bias modification (CBM) for facial interpretation, a digital health intervention that changes our perception for emotional ...

Teens who help strangers have more confidence, study finds

December 18, 2017
Tis the season for helping at a soup kitchen, caroling at a care facility or shoveling a neighbor's driveway.

Suicidal thoughts rapidly reduced with ketamine, finds study

December 14, 2017
Ketamine was significantly more effective than a commonly used sedative in reducing suicidal thoughts in depressed patients, according to researchers at Columbia University Medical Center (CUMC). They also found that ketamine's ...

Do bullies have more sex?

December 14, 2017
Adolescents who are willing to exploit others for personal gain are more likely to bully and have sex than those who score higher on a measure of honesty and humility. This is according to a study in Springer's journal Evolutionary ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.